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Abstract 
 
Retinal dystrophies are an overlapping group of genetically heterogeneous 
conditions resulting from mutations in over 250 genes. Here we describe four 
families affected by an adult onset retinal dystrophy with initial macular degeneration 
that is characterized by central visual loss in the third/fourth decade of life where the 
affected individuals were found to harbor disease-associated variants in DRAM2 
(DNA-damage regulated autophagy modulator protein 2). Homozygosity mapping 
and exome sequencing in a large, consanguineous British family of Pakistani origin 
revealed a homozygous frameshift variant (c.140delG, p.Gly47Valfs*3) in nine 
affected family members. Then, Sanger sequencing of DRAM2 in 322 retinal-
dystrophy unrelated probands revealed one European subject with compound 
heterozygous DRAM2 changes (c.494G>A, p.Trp165* and c.131G>A, p.Ser44Asn). 
Independently, a gene-based case-control association study was conducted using 
an exome sequencing dataset of 18 phenotypically similar cases and 1,917 controls. 
Using a recessive model and a binomial test for rare, presumed biallelic, variants, 
DRAM2 was found to be the most statistically-enriched gene; one subject was a 
homozygote (c.362A>T, p.His121Leu) and another a compound heterozygote 
(c.79T>C, p.Tyr27His and c.217_225del, p.73_75del). DRAM2 is a transmembrane 
protein that has previously been localized to lysosomes and has been implicated in 
inducing autophagy. Immunohistochemical analysis showed DRAM2 co-localisation 
with rhodopsin in the photoreceptor outer segment where lysosomes are absent. 
This surprising observation suggests a novel role for DRAM2 in the retina. 
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Retinal dystrophies are a clinically and genetically heterogeneous group of disorders 
characterized by progressive photoreceptor degeneration.1 The pattern of visual loss 
and retinal appearance varies and is related to the degree to which cone and rod 
photoreceptors are affected. In subjects with retinitis pigmentosa (RP), for example, 
the rods are affected more severely and earlier than the cones, and the presenting 
symptoms are typically night blindness and/or visual field loss. Disorders in which the 
cones are more severely affected than the rods include macular dystrophies (MD; 
localized loss of central/macular cones as a primary or secondary event) and cone-
rod dystrophies (CRD; central and peripheral cone involvement). MD and CRD show 
clinical overlap and loss of central vision is often the common presenting symptom. 
Frequently, subjects with CRD also report light sensitivity, a symptom which can 
suggest generalized cone system dysfunction. Assigning a disease category can be 
challenging and confounding factors include inter- and intra-familial phenotypic 
variability and the presence of age-dependent phenotypic transitions. RP, MD and 
CRD can be transmitted in a dominant, recessive or X-linked manner and, to date, 
variants in 73, 16 and 30 genes respectively have been shown to give rise to these 
conditions (RetNet, accessed October 2014).  
 
The initial aim of this study was to identify the genetic basis of an adult-onset retinal 
dystrophy with early macular involvement (Figure 1) in a consanguineous Pakistani 
family with multiple affected members living in the UK (family ES1; Figure 2). 
Affected individuals became symptomatic early in the third decade, describing 
increasing difficulty with close visual tasks. Neither light sensitivity nor night 
blindness were significant early symptoms. There was progressive loss of visual 
acuity in all symptomatic individuals but only three of eleven reported light sensitivity 
as the condition progressed; difficulty seeing in dim illumination was an inconsistent 
feature. Fundus examination revealed maculopathy in all symptomatic individuals 
tested, with peripheral retinal degeneration being a frequent finding in older subjects. 
Notably, optical coherence tomography (OCT) imaging in the pre-symptomatic 
second decade (subject IV.8, family ES1; Figure 2) suggested early para-central 
photoreceptor degeneration (loss of the photoreceptor layer and ellipsoid zone in the 
para-foveal area).  
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This study was approved by the Leeds East (Project number 03/362) and Moorfields 
Eye Hospital Research Ethics Committees and adhered to the tenets of the 
Declaration of Helsinki. Peripheral blood was collected from affected individuals, 
parents and unaffected relatives where these were available. Genomic DNA was 
extracted from blood leukocytes according to standard procedures.  
 
Homozygosity mapping was performed using Affymetrix 250K single nucleotide 
polymorphism (SNP) arrays on genomic DNA from seven affected individuals from 
family ES1. Data were analysed with the AgileMultiIdeogram software. Two 
homozygous regions were shared among all seven affected individuals: a 10.1Mb 
interval on chromosome 1 (between rs6677953 and rs814987; containing 160 
genes) and a 2.9Mb region on chromosome 7 (between rs17140297 and 
rs12706292; containing 5 genes) (Figure S1). Given the absence of genes 
previously reported to be associated with retinal dystrophy within these intervals, a 
whole exome sequencing (WES) strategy was utilized to identify the molecular 
pathology in the family. DNA from one affected family member (subject IV.6, family 
ES1; Figure 2) was analysed. For exon capture, the SureSelectXT Human All Exon 
V4 target enrichment reagent (Agilent) was used; paired-end sequencing was 
performed on a HiSeq2000 system (Illumina). The raw sequence data files were 
processed on the Galaxy platform2 and aligned to the human reference genome 
sequence (hg19/GRCh37) using Bowtie2.3 The alignment was processed in BAM 
format4 with Picard and the Genome Analysis Toolkit5 to correct alignments around 
insertions-deletions, and to identify and remove duplicates and sequencing reads 
with quality scores less than 20. The Unified Genotyper6 reported variants in the 
VCF format which were annotated using ANNOVAR.7 We excluded variants (i) with a 
read depth of less than 10, (ii) that are outside the exon and flanking two base-pair 
splice donor and acceptor sites, (iii) that are synonymous and (iv) with a minor allele 
frequency (MAF) >1% in the NHLBI Exome Sequencing Project Exome Variant 
Server (EVS; release version v.0.0.30). A list of the 33 homozygous variants 
remaining after filtration is shown in Table S1. Only one of these sequence 
alterations mapped within the shared regions of homozygosity identified in family 
ES1. This was a homozygous single-base deletion in DRAM2 (DNA-damage 
regulated autophagy modulator protein 2 [MIM 613360], NM_178454.4), that creates 
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a frameshift and is predicted to lead to premature truncation of the protein 
(c.140delG, p.Gly47Valfs*3). Segregation of this variant with the disease in the 
family (Figure 2) was confirmed by Sanger sequencing of DRAM2 exon 4 (Figure 3A; 
primer pairs are shown in Table S2). This change was excluded from 159 ethnically 
matched control individuals and was not present in the dbSNP and EVS databases. 
It was found once in heterozygous state in WES data from 61,486 unrelated 
individuals sequenced as part of various disease-specific and population genetic 
studies (accessed via. the Exome Aggregation Consortium [ExAC] browser, version 
0.2). Notably, no homozygous presumed loss-of-function variant in DRAM2 was 
present in the ExAC dataset. A maximum two point LOD score of 2.4 was obtained 
between c.140delG and the disease in nine genotyped family members using 
Superlink.8 For this analysis the c.140delG change was treated as a genetic marker 
with a MAF of 0.01%, and the disease was assumed to segregate in the family in a 
recessive fashion with full penetrance.  
 
In an attempt to identify further families with DRAM2-associated retinopathy, the 
seven coding DRAM2 exons and flanking splice sites, were PCR amplified and 
Sanger sequenced in 74 individuals diagnosed with RP, 154 with CRD or MD and 94 
with infantile-onset retinal dystrophy (Leber Congenital Amaurosis) (primer pairs are 
shown in Table S2). This screen identified an isolated female case (subject 1325) of 
European ancestry in the CRD/MD panel that was compound heterozygous for a 
nonsense variant in exon 6 (c.494G>A, p.Trp165*) and a missense change in exon 3 
(c.131G>A, p.Ser44Asn). The latter affects a serine residue that is highly conserved 
from human to nematodes (Figures 3 and S2). This missense change was predicted 
to be pathogenic by a number of bioinformatics prediction tools (Table S3) and was 
not present in dbSNP, EVS or ExAC databases. The p.Trp165* change is an 
annotated variant in dbSNP (rs201422368) with a MAF of 0.008% (1/13,003) in EVS 
and 0.003% (3/118,572) in ExAC; it is only reported in heterozygous state in these 
databases. Subject 1325 experienced blurred vision at age 29 and was soon after 
found to have maculopathy on fundus examination. At age 35, she also complained 
of night vision problems and sensitivity to light; fundus examination revealed mild 
peripheral retinal degeneration in addition to the maculopathy. At the age of 47, she 
had acuity of 1.0 logMAR in each eye and electrophysiology revealed severely 
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attenuated or absent dark- and light-adapted electroretinograms (ERGs) and pattern 
ERGs (Figure S3).  
 
Independently, in a study designed to identify novel genes causative of recessive 
macular dystrophy, 28 families from the inherited retinal disease clinics at Moorfields 
Eye Hospital, London were ascertained. Details on this cohort have been previously 
reported.9 Briefly, the main inclusion criteria were a CRD or MD phenotype, an 
absence of retinal imaging findings suggestive of ABCA4-associated retinopathy and 
a negative screen for ABCA4 mutations and other known retinal disease genes using 
AsperBiotech APEX technology and Sanger sequencing of other candidate genes. 
DNA samples from the 28 probands were extracted and analyzed by WES (exon 
capture by SureSelectXT Human All Exon V5, Agilent; sequencing by HiSeq2000, 
Illumina). Downstream analysis and variant filtering were performed as previously 
described. The molecular diagnosis was identified in 10 of 28 families (methods and 
results have been reported before).9 On the 18 unsolved cases, a gene based case-
control association analysis was performed using exome sequencing data from a 
consortium of UK based researchers (“UCL-exomes”). Aiming to minimize bias,10 
UCL-exomes controls were initially split between two sets. The first set of 500 
randomly selected samples was used in conjunction with EVS to determine variant 
frequency for inclusion in case control tests. In that context, “rare” variants are 
variants with MAF<0.5% in EVS and no more than 2 occurrences in this first set of 
500 UCL-exomes control samples. The second set of 1,917 unrelated UCL-exomes 
controls was used to directly compute gene based association p-values, using a 
recessive disease mode, i.e. samples were labeled as potential carriers only if they 
carried at least two rare (using the definition stated above) and potentially functional 
(presumed loss-of-function, non-synonymous or splice site altering) variants. A 
binomial test was used for excess of such potential bi-allelic variants in the 18 cases 
compared to the 1,917 controls (Table S4). 
 
The most significant gene-based p-value was obtained for DRAM2 (Table S4). Two 
of the 18 cases were found to harbor likely disease-associated variants in this gene. 
A 37-year-old female proband (family gc17004, Figure 2) of European ancestry was 
a compound heterozygote for a missense variant (c.79T>C, p.Tyr27His) and an in-
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frame deletion (c.217_225del, p.73_75del). Furthermore, a 47-year-old male 
proband of South Asian origin (family gc4728, Figure 2; parents not knowingly 
related) was homozygous for a missense change (c.362A>T, p.His121Leu). None of 
these three changes was present in dbSNP, EVS or ExAC and both missense 
variants (p.Tyr27His and p.His121Leu) were evolutionarily conserved from human to 
nematodes (Figure S2) and reported to be pathogenic by a number of prediction 
tools (Table S3). All changes were confirmed by Sanger sequencing (Figure 3) and 
segregated with the disease phenotype in the family as expected for a recessive 
condition (Figure 2).  
 
Both probands presented with central visual loss (at age 29 for the proband of family 
gc17004 and at age 39 for the proband of family gc4728). At presentation, there was 
no light sensitivity or night blindness. Fundus examination and retinal imaging 
revealed macular photoreceptor loss with an apparently normal peripheral retina. 
These observations were consistent with electrophysiological findings which in both 
showed macular dysfunction (attenuated pattern ERG) with no evidence of 
generalised retinal involvement (dark- and light-adapted ERGs were within normal 
limits). Notably, 8 years after presentation, the central areas of atrophy have 
expanded and peripheral changes were observed. Electrodiagnostic testing was 
repeated and revealed more widespread retinal dysfunction in both cases. The 
phenotype was notably similar to the affected members of family ES1 and subject 
1325 described above.  
 
Given that affected members of family ES1 are homozygous for a DRAM2 variant 
that is likely to lead to either nonsense mediated decay of the encoded mRNA, or to 
a truncated protein of only 47 amino acids, the molecular pathology of the disease is 
likely to be loss of DRAM2 function. This speculation is further supported by the 
biallelic state and predicted severity of the additional five likely disease-causing 
variants identified as well as by the similar phenotype in all four families. 
 
DRAM2, also known as TMEM77 (transmembrane protein 77), encodes a 266 amino 
acid protein containing six putative transmembrane domains (Figure 3B). Previous 
overexpression studies in HEK293 cells localised it to lysosomal membranes11,12 
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where it initiates the conversion of endogenous LC3-I (microtubule-associated 
protein light chain 3) to the general autophagosome marker protein, LC3-II (LC3-
1/phosphatidylethanolamine conjugate). This suggests that DRAM2 induces the 
autophagy process.11 Autophagy is a natural cell survival mechanism triggered in 
response to stress stimuli such as nutrient starvation or the accumulation of 
damaged organelles. It is responsible for degrading and recycling cytoplasmic 
proteins and lipids as well as organelles within the cell.13 This usually begins with 
isolation of the macromolecules and organelles within the cytoplasm into single 
membrane vesicles, which fuse together to produce an autophagosome. These 
autophagosomes subsequently fuse with lysosomes containing acid hydrolases and 
form a double-membrane autolysosome.14,15 Although the aim of autophagy is to 
relieve cellular stress, its excessive induction can in some cases lead to apoptosis 
rather than protection from cell death.16 
 
There is also some evidence to suggest that DRAM2 may have tumour suppressor 
capability. DRAM2 transcript and protein expression are reduced in ovarian tumours 
compared to normal matched tissues.11 Also, siRNA knockdown of endogenous 
DRAM2 results in reduced conversion to LC3-II in cells subject to starvation-induced 
autophagy17 and increased survival in deoxyrubicin treated cells that would normally 
undergo p53-mediated apoptosis.11 We note that examination of medical histories in 
the reported subjects with DRAM2-associated retinal dystrophy provided no 
evidence of increased susceptibility to cancer. 
 
Although DRAM2 is transcribed ubiquitously (Figure S4),12 in light of the finding that 
human DRAM2 variants cause retinal dystrophy, we investigated the precise 
distribution of the normal protein in the mouse retina. Serial sections were taken from 
mouse eyes at postnatal day 30 and were stained with a goat polyclonal antiserum 
against DRAM2 (Figure 4). Confocal immunofluorescence microscopy showed that 
DRAM2 co-localized with rhodopsin to the outer segment of the photoreceptor layer. 
This coincides with the primary pathology observed on pre-symptomatic OCT 
analysis in which photoreceptor outer segments appeared specifically affected 
(Figure 1). However, this result is unexpected as the photoreceptor outer segments 
are thought to be devoid of lysosomes. Autophagy takes place in the cytoplasm, so a 
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role in photoreceptor autophagy would predict localization in the photoreceptor inner 
segments. Given the disc shedding process and requirement to recycle 
phototransduction components, a high level of autophagy occurs in the RPE. Given 
that outer segments consist almost entirely of densely packed membrane discs filled 
with phototransduction cascade proteins, these data therefore suggest that DRAM2, 
a transmembrane protein, localizes to disc membranes where its precise role is 
unknown.  
 
To summarize, we have shown that biallelic missense, nonsense and frameshift 
variants in DRAM2 cause retinal dystrophy with early macular cone photoreceptor 
involvement. The clinical features and course of retinal degeneration were highly 
similar among affected individuals from the four reported families. Our findings 
suggest that DRAM2 is essential for photoreceptor survival and further studies are 
expected to provide important insights into its role in the photoreceptor outer 
segments. 
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Web Resources 
 
The URLs for data presented herein are as follows: 
 
AgileMultiIdeogram, http://dna.leeds.ac.uk/agile/AgileMultiIdeogram/ 
ANNOVAR, http://www.openbioinformatics.org/annovar/ 
CADD, http://cadd.gs.washington.edu/  
ClustalW, http://www.ebi.ac.uk/clustalw2/ 
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ 
ExAC browser, http://exac.broadinstitute.org/  
Galaxy, https://usegalaxy.org 
GATK, http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Tool
kit 
IGV (Interactive Genomics Viewer), http://www.broadinstitute.org/software/igv/ 
Mutation Taster, http://www.mutationtaster.org/  
MutPred, http://mutpred.mutdb.org/  
NHLBI Exome Sequencing Project Exome Variant Server (EVS), 
http://evs.gs.washington.edu/  
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org/ 
Picard, http://picard.sourceforge.net/ 
PolyPhen2, http://genetics.bwh.harvard.edu/pph2/  
Primer3, http://frodo.wi.mit.edu/cgi-bin/primer3/ 
PROVEAN, http://provean.jcvi.org/ 
RetNet, https://sph.uth.edu/retnet/home.htm 
SIFT, http://sift.jcvi.org/ 
Superlink, http://cbl-hap.cs.technion.ac.il/superlink-snp/ 
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Figure 1. Clinical features of individuals from family ES1 with retinal dystrophy 
and early maculopathy caused by recessive DRAM2 mutations. 
Colour fundus photograph (A), fundus autofluorescence (C), infra-red reflectance (E) 
and OCT (F) images from the right eye of case IV.8 at 25 years. A colour fundus 
photograph (B), fundus autofluorescence (D) infra-red reflectance (G) and OCT 
image (H) from a normal control individual are provided for comparison. There is a 
dull foveal reflex on fundus photography. On autofluorescence imaging, there is a 
central area of reduced autofluorescence with a ring of increased autofluorescence. 
On OCT imaging, there is loss of the outer nuclear, external limiting membrane and 
ellipsoid layers in the central macula. The composite colour photograph from the left 
eye of case III.1, at the age of 48, shows macular atrophy with white dots in the 
temporal macula and intra-retinal pigment migration, extending towards the equator 
(I). On the infra-red reflectance images, the horizontal green lines show the position 
and direction of the corresponding OCT scan. The scale bars represent 200μm. 
 
Figure 2. Pedigrees of families/cases reported in this study and DRAM2 
mutation segregation data.  
Affected individuals are shaded black. The maternal grandmother of individual 
gc17004 has age-related macular degeneration in her 90s (shaded grey). The 
genotypes for all tested family members are shown below each individual, with M 
representing the mutant allele and + representing the wild-type allele. 
 
Figure 3. Variants in DRAM2 cause retinal dystrophy.  
(A) Schematic representation of the DRAM2 genomic structure and major transcript 
(NM_178454.4) showing the location and sequence traces of the six disease-
causing variants identified in this study. (B) Schematic diagram of the DRAM2 
protein showing the location of the affected amino-acids within the protein domains. 
 
Figure 4. Localization of Dram2 in photoreceptor outer segments.  
Radial 6μm cryosections of mature mouse retina (P30) were labeled with anti-Dram2 
(M-12, Santa Cruz Biotechnology) and anti-Rhodopsin (Sigma-Aldrich) followed by 
the secondary antibody Alexa Fluor 488-conjugated donkey anti-goat 
immunoglobulin (green) (Molecular Probes Incorporation) and Alexa Fluor 568-
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conjugated goat anti-rabbit immunoglobulin (red) (Invitrogen) respectively, and the 
nuclei counterstained with DAPI (Vector Laboratories). Immunofluorescence was 
analyzed with an Eclipse TE2000-E inverted confocal microscope (Nikon 
Instruments) and shows co-localisation of dram2 with rhodopsin to the outer 
segment of the photoreceptor layer (POS). The other layers are the retinal pigment 
epithelial layer (RPE), outer nuclear layer (ONL), outer plexiform layer (OPL), inner 
nuclear layer (INL), inner plexiform layer (IPL) and the ganglion cell layer (GCL). 
Scale bars represents 50μm. 
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